Fortrea

Fortrea advances innovation in clinical trials with agile CRO solutions for biopharma across Phase I–IV trials, delivering flexible models and data-driven clinical solutions.

Fortrea’s clinical pharmacology services support early-phase trials with PK/PD modeling, biometric services, and patient safety insights.

Fortrea clinical trial consulting services deliver science-based CRO guidance across regulatory strategy, product development & market access and HEOR consulting services.

Fortrea delivers clinical development across clinical trial therapeutic areas, supported by deep therapeutic expertise and global research capabilities.

Fortrea white paper on cardiometabolic rare diseases focused on rare disease research insights, cardiometabolic disorders, evolving clinical understanding, and research considerations affecting rare disease studies.

Explore Fortrea Insights for blogs, brochures, case studies, info sheets, news articles, podcasts, reports, resources, review articles, videos, webinars and white papers across therapeutic areas, clinical specialties and development phases.

Hear from biopharma and biotech leaders as they discuss trends, challenges, and breakthroughs in clinical development on the Fortrea Podcast.

Fortrea’s leadership team consists of experienced executives in clinical research and development who guide global strategy and operations.

Fortrea’s experts provide science-driven guidance in clinical, regulatory, and therapeutic areas for complex development programs.

Fortrea offers global clinical development capabilities, therapeutic expertise, and a patient-focused approach backed by over 30 years of experience.

Fortrea’s culture fosters collaboration, integrity, and innovation to advance clinical development worldwide.

Fortrea emphasizes quality in clinical development through industry best practices, process enhancements, and global regulatory compliance.

Contact Fortrea to connect with clinical research, oncology, biometrics, market access, and drug development experts supporting global clinical trials and consulting services.

Fortrea operates global offices supporting clinical development programs in North America, Europe, and Asia-Pacific.

Fortrea, a clinical research organization, delivers patient-focused solutions to accelerate clinical development and bring therapies to patients.

Fortrea releases its financial performance for Q3 2026, covering the period ending September 30. The report outlines key metrics and operational updates for the quarter. Investors and stakeholders review the results for insights into the company’s growth trajectory and financial health.

Oct 2026FortreaNews article

Fortrea, a global contract research organization (CRO), announces CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will attend the Jefferies Global Healthcare Conference. The company engages in investor relations events to discuss its operations and growth in clinical research services.

Oct 2026FortreaNews article

Fortrea and Omico are partnering to accelerate cancer research by matching patients with biomarker-led clinical trials. The collaboration leverages Omico’s precision oncology screening network and Fortrea’s contract research expertise to improve trial enrollment. Both companies aim to enhance drug development in oncology through targeted patient selection.

Oct 2026FortreaNews article

Fortrea acquires Worldwide Clinical Trials’ Early Phase Services division, including a Clinical Research Unit and Bioanalytical Laboratory, in an all-cash deal. The transaction expands Fortrea’s early-stage clinical trial capabilities. The acquisition is valued at approximately $45 million.

Oct 2026FortreaNews article